The era of the integrase strand transfer inhibitors (INSTI s) for the treatment of human
immunodeficiency virus (HIV) infection began with raltegravir in 2007. Since that time …

Abstract Purpose of Review With the expanded roll-out of antiretrovirals for treatment and
prevention of HIV during the last decade, the emergence of HIV drug resistance (HIVDR) …

Drug delivery approaches can be used to enhance the bioavailability of current antiretroviral
drugs used to treat HIV. Lipid nanocarriers are attractive drug delivery vehicles and these …

Background Dolutegravir (DTG) and boosted darunavir (bDRV) are potent antiretrovirals
with a high resistance barrier and might be valuable switch options for people with HIV …

Objectives Dolutegravir is widely prescribed owing to its potent antiviral activity, high genetic
barrier and good tolerability. The aim of this study was to characterize dolutegravir's …

Nuclear localization signal (NLS) of HIV-1 integrase (IN) is implicated in nuclear import of
HIV-1 preintegration complex (PIC). Here, we established a multiclass drug-resistant HIV-1 …

Abstract Human Immunodeficiency Virus (HIV) is a global health concern to which
nanomedicine approaches provide opportunities to improve the bioavailability of existing …

Introduction: Modern antiretroviral therapy (ART) has revolutionized HIV treatment. ART
regimens are now highly efficacious, well-tolerated, safe, often with one multi-drug pill, once …

Objective: To review available evidence for dolutegravir-based dual therapy as maintenance
treatment in HIV-1 infected patients. Data Sources: A literature search was conducted using …

Introduction: Darunavir (DRV) was the last approved protease inhibitor (PI) and has been
extensively used for the treatment of HIV in both naïve and experienced subjects due to its …